Quarterly Activity Report and Appendix C

Quarterly Activity Report – Period ending 30 June 2020

Q2 Highlights:

  • Company announces plans for the Phase I first-in-human study to be undertaken in Australia

    with commencement expected in Q4

  • Manufacturing of the MagSenseTM HER2 nanoparticle formulation for use in a first in human

    study has proceeded on plan

  • Cash balance of $4.2M at 30 June 2020; subsequent to 30 June additional $4.7M received (net

    of costs) from oversubscribed placement

  • Additional funding provides capital to support company beyond Phase I study completion

    and accelerate additional product plans

  • Di Angus appointed non-executive Director

Read the Quarterly Activity Report and Appendix C.